ChromoCure, Inc. adds new regional sales and executive offices in Florida to cover Southeastern United States
24 Setembro 2009 - 10:30AM
PR Newswire (US)
RENO, NV, Sept. 24 /PRNewswire-FirstCall/ -- ChromoCure, Inc.
(PINKSHEETS: KKUR) announced today it has added regional sales and
executive offices in Aventura Florida with Dr. Jay Ellenby. Dr.
Ellenby will provide sales support and business development for the
Southeastern United States. Dr. Ellenby is a member of the
Company's Board of Advisors and will be the Business and Sales
Director for the entire Southeastern United States. Today's
announcement and the recent appointment of the Company's Lead
Pathologist Dr. Mikhail Kantius to the Board of Advisors is a
continuation of the Company's strategic plans to establish regional
sales and executive offices to promote and distribute the Company's
technology and solutions. The Company now has business development
team member for both the Northeastern and Southeastern United
States. Updates will be released on the following strategic goals:
- Initial sales and installations of the Company's systems and
technology - Acquisition of profitable diagnostic labs to expand
the company's operations - Release of technology and industry White
Papers, industry commentary, and sales revenue models. About
ChromoCure ChromoCure develops and provides proprietary cancer
detection systems. The Company owns its technology and provides its
systems on a revenue sharing basis. The Company's systems measure
the unique genomic characteristic found in 100% of all cancers and
never found in normal cells. The Company believes its technology
has an effective accuracy of 100% for all cancers at all stages.
The Company believes its technology superior and will become the
gold standard for cancer detection worldwide. The Company's
technology and understanding of cancer also suggest non-toxic and
non-invasive approaches to cancer therapy and cure research. The
Company will release progress reports on these initiatives from
time to time. Safe-Harbor Statement This release contains
statements or projections regarding future performance that are
forward-looking statements as defined in the Private Securities
Litigation Reform Act of 1995. Actual results may differ materially
from those projected as a result of certain risks and
uncertainties. The company's filings contain various RISK FACTORS
(and are incorporated herein by reference) and should be read
before any investment decision. Investor Relations: Contact:
ChromoCure, Inc. Tel 1.775.636.6548 DATASOURCE: ChromoCure, Inc.
CONTACT: ChromoCure, Inc., , Tel (775) 636-6548
Copyright